NCPA Attends FDA Compounding Listening Session:  This week, NCPA participated in a “listening session” at FDA headquarters regarding implementation of the Drug Quality and Security Act (DQSA).  The session allowed FDA officials to hear pharmacy stakeholder concerns regarding implementation and to ask questions. FDA will be holding separate listening sessions with different interest groups.  NCPA’s concerns, as were echoed by many of the organizations in attendance centered on the importance of leaving office use compounding under state control, as well as the infeasibility of one standard Memorandum of Understanding (MOU) that would apply to interstate shipments of compounds.  Much of the discussion also surrounded the importance of the need for clarity around certain definitions associated with compounding.  NCPA and the other pharmacy related organizations in attendance will be following up with FDA in response to specific questions

quoted from here